New Zealand markets closed

Laboratory Corporation of America Holdings (LH)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
218.41+3.76 (+1.75%)
At close: 04:00PM EDT
218.99 +0.58 (+0.27%)
After hours: 06:25PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close214.65
Open213.76
Bid218.02 x 800
Ask218.99 x 800
Day's range212.22 - 218.60
52-week range200.32 - 280.72
Volume642,305
Avg. volume623,054
Market cap19.329B
Beta (5Y monthly)1.06
PE ratio (TTM)15.53
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield2.88 (1.32%)
Ex-dividend date22 Feb 2023
1y target estN/A
  • Business Wire

    Ovia HealthTM Expands Digital Platform Capabilities to Include Menopause Tracking

    BOSTON, February 22, 2023--Ovia Health, a trusted digital health platform for women and families, today announced the expansion of its Ovia® app, which will now allow women to track menopause symptoms and access valuable resources and support to address the transition to menopause/perimenopause. The technology is available through Ovia’s consumer application and enterprise offerings for employers and health plans.

  • Business Wire

    Labcorp Announces 2022 Fourth Quarter and Full-Year Results

    BURLINGTON, N.C., February 16, 2023--Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the fourth quarter and year ended Dec. 31, 2022, full-year 2023 guidance.

  • Business Wire

    Labcorp Unveils New Name for Future Independent Clinical Development Business - Fortrea

    BURLINGTON, N.C., February 09, 2023--Labcorp (NYSE: LH), a leading global life sciences company, today announced that the new company to be formed by the planned spin-off of its Clinical Development business will be known as Fortrea. Upon completion of the spin-off from Labcorp, Fortrea will operate as an independent, publicly traded global CRO that offers comprehensive drug and medical device development services. With over 19,000 people, Fortrea will provide Phase I through IV clinical trial m